Therapeutic Use of a Selective S1P1 Receptor Modulator Ponesimod in Autoimmune Diabetes

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  You, Sylvaine ^a,b   Piali, Luca ^c   Kuhn, Chantal ^a,b   Steiner, Beat ^c   Sauvaget, Virginia ^a,b   Valette, Fabrice ^a,b   Clozel, Martine ^c   Bach, Jean François ^a,b   Chatenoud, Lucienne ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

145 2C11 F(AB')2 FRAGMENT; CD3 ANTIBODY; GLUCOSE 6 PHOSPHATASE; ISLET SPECIFIC GLUCOSE 6 PHOSPHATASE CATALYTIC SUBUNIT RELATED PROTEIN; PONESIMOD; SPHINGOSINE 1 PHOSPHATE 1 RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; ANTIBODY; ANTIDIABETIC AGENT; CD3 ANTIGEN; G6PC2 PROTEIN, MOUSE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DIABETES; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG WITHDRAWAL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; RECURRENT DISEASE; RELAPSE; REMISSION; T LYMPHOCYTE; ADOPTIVE TRANSFER; ANIMAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPH NODE; NONOBESE DIABETIC MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; SPLEEN;

ADMINISTRATION, ORAL; ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES; ANTIGENS, CD3; B-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION; GLUCOSE-6-PHOSPHATASE; HYPOGLYCEMIC AGENTS; LYMPH NODES; LYMPHOCYTE COUNT; MICE; MICE, INBRED NOD; RECEPTORS, LYSOSPHINGOLIPID; RECURRENCE; SELF TOLERANCE; SPLEEN; T-LYMPHOCYTES; THIAZOLES;

EID: 84886256822     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077296     Document Type: Article

References (50)

1. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, et al. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346-349.
2. Ledgerwood LG, Lal G, Zhang N, Garin A, Esses SJ, et al. (2008) The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nat Immunol 9: 42-53.
3. Schwab SR, Cyster JG, (2007) Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 8: 1295-1301.
4. Brinkmann V, Lynch KR, (2002) FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 14: 569-575.
5. Brinkmann V, Pinschewer D, Chiba K, Feng L, (2000) FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci 21: 49-52.
6. Nikolova Z, Hof A, Baumlin Y, Hof RP, (2001) Combined FTY720/cyclosporine A treatment promotes graft survival and lowers the peripheral lymphocyte count in DA to lewis heart and skin transplantation models. Transpl Immunol 8: 267-277.
7. Webb M, Tham CS, Lin FF, Lariosa-Willingham K, Yu N, et al. (2004) Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 153: 108-121.
8. Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, et al. (2002) Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol 29: 707-716.
9. Matsuura M, Imayoshi T, Okumoto T, (2000) Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. Int J Immunopharmacol 22: 323-331.
10. Daniel C, Sartory NA, Zahn N, Schmidt R, Geisslinger G, et al. (2007) FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions. Mol Immunol 44: 3305-3316.
11. Maki T, Gottschalk R, Monaco AP, (2002) Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice. Transplantation 74: 1684-1686.
12. Maki T, Gottschalk R, Ogawa N, Monaco AP, (2005) Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720. Transplantation 79: 1051-1055.
13. Salvadori M, Budde K, Charpentier B, Klempnauer J, Nashan B, et al. (2006) FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 6: 2912-2921.
14. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355: 1124-1140.
15. Kabashima K, Haynes NM, Xu Y, Nutt SL, Allende ML, et al. (2006) Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. J Exp Med 203: 2683-2690.
16. Lo CG, Xu Y, Proia RL, Cyster JG, (2005) Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med 201: 291-301.
17. Bolli MH, Abele S, Binkert C, Bravo R, Buchmann S, et al. (2010) 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem 53: 4198-4211.
18. Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, et al. (2011) The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther 337: 547-556.
19. You S, Chen C, Lee WH, Wu CH, Judkowski V, et al. (2003) Detection and characterization of T cells specific for BDC2.5 T cell-stimulating peptides. J Immunol 170: 4011-4020.
20. Enee E, Martinuzzi E, Blancou P, Bach JM, Mallone R, et al. (2008) Equivalent specificity of peripheral blood and islet-infiltrating CD8+ T lymphocytes in spontaneously diabetic HLA-A2 transgenic NOD mice. J Immunol 180: 5430-5438.
21. Chatenoud L, Bluestone JA, (2007) CD3-specific antibodies: a portal to the treatment of autoimmunity. Nature Reviews Immunology 7: 622-632.
22. You S, Thieblemont N, Alyanakian MA, Bach JF, Chatenoud L, (2006) Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol Rev 212: 185-202.
23. Penaranda C, Tang Q, Ruddle NH, Bluestone JA, (2010) Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes 59: 1461-1468.
24. Lepault F, Gagnerault MC, (1998) L-selectin(-/lo) and diabetogenic T cells are similarly distributed in prediabetic and diabetic nonobese diabetic mice. Lab Invest 78: 551-558.
25. You S, Belghith M, Cobbold S, Alyanakian MA, Gouarin C, et al. (2005) Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 54: 1415-1422.
26. Stadinski BD, Delong T, Reisdorph N, Reisdorph R, Powell RL, et al. (2010) Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 11: 225-231.
27. Lehmann PV, Forsthuber T, Miller A, Sercarz EE, (1992) Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358: 155-157.
28. Miller SD, Vanderlugt CL, Begolka WS, Pao W, Yauch RL, et al. (1997) Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med 3: 1133-1136.
29. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, et al. (1993) Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 366: 72-75.
30. Kaufman DL, Clare-salzler M, Tian J, Forsthuber T, Ting GSP, et al. (1993) Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366: 69-72.
31. Krishnamurthy B, Dudek NL, McKenzie MD, Purcell AW, Brooks AG, et al. (2006) Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. Journal of Clinical Investigation 116: 3258-3265.
32. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, et al. (2005) Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435: 220-223.
33. Battaglia M, Stabilini A, Draghici E, Migliavacca B, Gregori S, et al. (2006) Induction of tolerance in type 1 diabetes via both CD4+CD25+ T regulatory cells and T regulatory type 1 cells. Diabetes 55: 1571-1580.
34. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, et al. (2006) Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212: 28-50.
35. Mauri C, Bosma A, (2012) Immune regulatory function of B cells. Annu Rev Immunol 30: 221-241.
36. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, et al. (2008) A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28: 639-650.
37. Lampropoulou V, Calderon-Gomez E, Roch T, Neves P, Shen P, et al. (2010) Suppressive functions of activated B cells in autoimmune diseases reveal the dual roles of Toll-like receptors in immunity. Immunol Rev 233: 146-161.
38. Chatenoud L, Thervet E, Primo J, Bach JF, (1994) Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 91: 123-127.
39. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, et al. (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352: 2598-2608.
40. Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, et al. (2010) Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53: 614-623.
41. Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, et al. (2011) Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet.
42. Chatenoud L, Primo J, Bach JF, (1997) CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158: 2947-2954.
43. You S, Zuber J, Kuhn C, Baas M, Valette F, et al. (2012) Induction of allograft tolerance by monoclonal CD3 antibodies: a matter of timing. Am J Transplant 12: 2909-2919.
44. Penaranda C, Tang Q, Bluestone JA, (2011) Anti-CD3 Therapy Promotes Tolerance by Selectively Depleting Pathogenic Cells while Preserving Regulatory T Cells. J Immunol 187: 2015-2022.
45. Chatenoud L, (2010) Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol 6: 149-157.
46. You S, Leforban B, Garcia C, Bach JF, Bluestone JA, et al. (2007) Adaptive TGF-{beta}-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A 104: 6335-6340.
47. Brossard P, Derendorf H, Xu J, Maatouk H, Halabi A, et al. (2013) Pharmacokinetics and Pharmacodynamics of Ponesimod, a Selective S1P Receptor Modulator, in the First-in-Human Study. Br J Clin Pharmacol.
48. Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, et al. (2004) Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 44: 532-537.
49. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, et al. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402-415.
50. Sobel K, Menyhart K, Killer N, Renault B, Bauer Y, et al. (2013) Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling. J Biol Chem 288: 14839-14851.